



Aloxi[®] (palonosetron) – First-time generic

- Generic versions of Eisai's [Aloxi \(palonosetron\)](#) 0.25 mg/5 mL injection were launched recently.
 - [Teva launched](#) a generic version on March 23, 2018.
 - [Dr. Reddy's launched](#) an [AP-rated](#) generic version on March 26, 2018.
 - [Cipla launched](#) an authorized generic version on March 26, 2018.
 - [Sandoz](#), [Exela](#) and [Fresenius Kabi](#) also received FDA approval to market generic Aloxi; however, launch plans from these manufacturers are pending.
- Aloxi is approved for the prevention of chemotherapy-induced nausea and vomiting in adults and pediatric patients aged 1 month to less than 17 years, and for the prevention of postoperative nausea and vomiting in adults.
 - Aloxi's 0.075 mg/1.5 mL injection has been discontinued.
- Palonosetron is also available in combination with netupitant as the branded [Akynzeo[®]](#) capsule.
 - Akynzeo is approved for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
- Aloxi had annual sales of approximately \$459 million in the U.S., according to IMS data as of November 2017.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.